Viral eye infection

Summary

Viral eye infection (MONDO:0020950) is a disease (an umbrella term covering 5 Mondo subtypes) with 4 GWAS associations across 7 studies and 2 clinical trials. A subtype of viral infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 5 Mondo subtypes
• GWAS associations: 4
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	viral eye infection
Mondo ID	MONDO:0020950
MeSH	D015828
SNOMED CT	312132001
UMLS	C0015407
MedGen	8753
Anatomy (UBERON)	UBERON:0000970
Is cancer (heuristic)	no

Also known as: EYE INFECT VIRAL · Eye Infection, Viral · Eye Infections, Viral · Infection, Viral Eye · Infection, Viral Ocular · Infections, Viral Eye · Infections, Viral Ocular · OCULAR INFECT VIRAL · Ocular Infection, Viral · Ocular Infections, Viral · VIRAL EYE INFECT · viral eye infection · Viral Eye Infections · Viral Ocular Infection · Viral Ocular Infections

Data availability: 4 GWAS associations (7 studies).

Disease family

This is a subtype of viral infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › viral eye infection

Related subtypes (40): Whitewater Arroyo hemorrhagic fever, exanthema subitum, Zika virus congenital syndrome, common wart, viral labyrinthitis, viral gastritis, vaccinia, viral esophagitis, Kaposi’s sarcoma, contagious pustular dermatitis, epidemic pleurodynia, herpangina, human T-lymphotropic virus 1 infectious disease, lumpy skin disease, milker’s nodule, molluscum contagiosum, Newcastle disease, pharyngoconjunctival fever, pseudorabies, Reoviridae infectious disease, immunodeficiency 32B, focal epithelial hyperplasia, neurolymphomatosis, viral myositis, virus-associated trichodysplasia spinulosa, infective dermatitis associated with HTLV-1, congenital varicella syndrome, viral hemorrhagic fever, arbovirus fever, human infection by orthopoxvirus, congenital Epstein-Barr virus infection, rabies, arbovirus infection, viral infection of central nervous system, viral respiratory tract infection, Parvoviridae infectious disease, COVID-19–associated multisystem inflammatory syndrome in children, primary viral infectious disease, disease arising from reactivation of latent virus, human betaherpesvirus 5 infectious disease

Subtypes (5): cytomegalovirus retinitis, herpes simplex virus keratitis, infectious epithelial keratitis, herpes zoster with dermatitis of eyelid, viral conjunctivitis

Genetics & variants

GWAS landscape

4 GWAS associations across 7 studies. Top hits map to 4 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs532422453	3e-11	CADPS	C	3.05
rs370179329	4e-11	LINC01721	G	2.63
rs144760739	2e-07	TMEM51-AS1	?
rs1807089	2e-07	LINC02810	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90477715	Verma A	2024	3,099	444,024	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90651962	Liu TY	2025	2,106	190,942	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90477714	Verma A	2024	881	119,404	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480082	Verma A	2024	881	119,404	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90651944	Liu TY	2025	628	217,632	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90481922	Verma A	2024	362	58,888	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90436001	Zhou W	2018	126	399,306	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	4

MAF distribution

Bucket	Variants
common (>=0.05)	2
low_freq (0.01-0.05)	0
rare (<0.01)	2
unknown	0

Functional consequences

Consequence	Count
intron_variant	4

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs532422453	3	62651210	C>T	0	intron_variant	CADPS	3e-11	Tier 4: intronic/intergenic
rs370179329	20	24091376	G>A	0.002	intron_variant	LINC01721	4e-11	Tier 4: intronic/intergenic
rs144760739	1	15124429	C>T	0.05	intron_variant	TMEM51-AS1	2e-07	Tier 4: intronic/intergenic
rs1807089	1	17738520	G>A	0.05	intron_variant	LINC02810	2e-07	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04374656	Not specified	COMPLETED	Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic
NCT04945850	Not specified	COMPLETED	Can COVID-19 Persist in Intraocular Fluid?